Illumina implements 'poison pill' with regard to Roche bid

27 January 2012

Responding to Swiss drug major Roche’s (ROG: SIX) hostile takeover over offer of $44.50 per share for US DNA sequencing firm Illumina (Nasdaq: ILMN) the latter has agreed to review the proposal valuing the company at around $5.7 billion and come up with recommendations to shareholders in due course (The Pharma Letter January 25).

However, Illumina also said that it has adopted a shareholder rights agreement – or “poison pill, designed to deter coercive or otherwise unfair takeover tactics, under which should a bidder become the owner of 15% or more of its stock, other shareholders would be able to exercise the rights to buy new common stock, diluting the stake of the prospective bidder.

Fair value, says Roche

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK